153 related articles for article (PubMed ID: 10855463)
1. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
[TBL] [Abstract][Full Text] [Related]
2. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.
Gex-Fabry M; Rudaz S; Balant-Gorgia AE; Brachet A; Veuthey JL; Balant LP; Bertschy G
Eur J Clin Pharmacol; 2002 Aug; 58(5):323-31. PubMed ID: 12185556
[TBL] [Abstract][Full Text] [Related]
3. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen K; Neuvonen PJ; Laine K
Clin Pharmacol Ther; 2008 Feb; 83(2):342-8. PubMed ID: 17687273
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects.
Ciusani E; Zullino DF; Eap CB; Brawand-Amey M; Brocard M; Baumann P
J Psychopharmacol; 2004 Dec; 18(4):559-66. PubMed ID: 15582923
[TBL] [Abstract][Full Text] [Related]
8. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
Levin GM; Nelson LA; DeVane CL; Preston SL; Eisele G; Carson SW
Psychopharmacol Bull; 2001; 35(2):62-71. PubMed ID: 12397887
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic options for treating major depression, and the role of venlafaxine.
Scott MA; Shelton PS; Gattis W
Pharmacotherapy; 1996; 16(3):352-65. PubMed ID: 8726593
[TBL] [Abstract][Full Text] [Related]
12. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
Hermann M; Hendset M; Fosaas K; Hjerpset M; Refsum H
Eur J Clin Pharmacol; 2008 May; 64(5):483-7. PubMed ID: 18214456
[TBL] [Abstract][Full Text] [Related]
14. Venlafaxine serum levels and CYP2D6 genotype.
Veefkind AH; Haffmans PM; Hoencamp E
Ther Drug Monit; 2000 Apr; 22(2):202-8. PubMed ID: 10774634
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
16. Time course of clinical response to venlafaxine: relevance of plasma level and chirality.
Gex-Fabry M; Balant-Gorgia AE; Balant LP; Rudaz S; Veuthey JL; Bertschy G
Eur J Clin Pharmacol; 2004 Feb; 59(12):883-91. PubMed ID: 14704834
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Paulzen M; Haen E; Hiemke C; Fay B; Unholzer S; Gründer G; Schoretsanitis G
J Affect Disord; 2018 Feb; 227():506-511. PubMed ID: 29156365
[TBL] [Abstract][Full Text] [Related]
18. Employing atmospheric pressure photoionization in liquid chromatography/tandem mass spectrometry to minimize ion suppression and matrix effects for the quantification of venlafaxine and O-desmethylvenlafaxine.
Theron HB; van der Merwe MJ; Swart KJ; van der Westhuizen JH
Rapid Commun Mass Spectrom; 2007; 21(10):1680-6. PubMed ID: 17465011
[TBL] [Abstract][Full Text] [Related]
19. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
